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Introduction
Polycythemia vera (PV) and essential thrombocythemia
(ET) are BCR-ABL-negative myeloproliferative neoplasms
characterized by clonal proliferation of multiple lineage pro-
genitor cells in bone marrow and by a relatively long median
survival. The clinical course of both diseases is characterized
by thrombosis as a major cause of morbidity and mortality1
and by long-term severe complications, such as evolution to
myelofibrosis (MF) or acute myeloid leukemia (AML), which
may occur in 2-25% of cases.2-5 Evolution to MF or AML is
almost universally characterized by the development of
cytopenias, due to progressive bone marrow failure, sympto-
matic splenomegaly and severe constitutional symptoms and
is associated with early death.6 Once transformation devel-
ops, current medical treatments, which mainly include sup-
portive therapy and/or cytoreductive treatment, are of limited
efficacy and scanty prospective. Allogeneic hematopoietic
stem cell transplantation (HSCT) is currently the only poten-
tially curative treatment for advanced PV or ET, with the 3-
year overall survival rate of patients so treated ranging from
39% to 67%.7-12
However, allogeneic HSCT is associated with a significant
mortality (approximately 30%)10,13,14 and morbidity, mainly
due to graft-versus-host disease (GVHD)8,15,16 with a clinical out-
come that is particularly poor in patients of advanced age or in
those with medical comorbidities.17 At present, the need for
and timing of allogeneic HSCT remain under debate18 since its
inherent risks are difficult to justify in patients with myelopro-
liferative neoplasms who are usually elderly, often have asso-
ciated comorbidities and given that the existing literature is
significantly under-powered for definite conclusions. 
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The clinical course of polycythemia vera and essential thrombocythemia is potentially associated with long-term
severe complications, such as evolution to myelofibrosis or acute myeloid leukemia. Allogeneic stem cell transplan-
tation is currently the only potentially curative treatment for advanced polycythemia vera or essential thrombo-
cythemia. We analyzed 250 consecutive patients with an initial diagnosis of polycythemia vera (n=120) or essential
thrombocythemia (n=130), who underwent transplantation due to progression to myelofibrosis (n=193) or acute
myeloid leukemia (n=57) and who were reported to the European Group for Blood and Marrow Transplantation
registry between 1994 and 2010. Their median age was 56 years (range, 22-75) and in 52% of cases the interval
between diagnosis and transplantation was 10 years or more. With a median follow-up from transplantation of 13
months, the 3-year overall survival rate and relapse incidence were 55% and 32%, respectively. In univariate analy-
sis, the main parameters that negatively affected post-transplantation outcomes were older age (>55 years), a diag-
nosis at transplant of acute myeloid leukemia and the use of an unrelated donor. The overall 3-year cumulative inci-
dence of non-relapse mortality was 28%, but was significantly higher in older patients than in younger ones (>55
years, 35% versus 20%, P=0.032), in those transplanted from an unrelated donor rather than a related donor (34%
versus 18%, P=0.034) and in patients with a diagnosis of acute myeloid leukemia compared to myelofibrosis (29%
versus 27%, P=0.045). This large retrospective study confirms that transplantation is potentially curative for patients
with end-stage polycythemia vera/essential thrombocythemia progressing to myelofibrosis or acute myeloid
leukemia. Relapse and non-relapse mortality remain unsolved problems for which innovative treatment approaches
need to be assessed.
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ABSTRACT
With this background, we carried out a retrospective
study analyzing post-HSCT survival outcome, response
rates and the relative contributions of different risk factors
on clinical outcome in a large number of patients with an
initial diagnosis of PV or ET who underwent allogeneic
HSCT due to progression to MF or AML. 
Methods
Patients and transplant characteristics
The individuals eligible for this study were 250 consecutive
patients with an initial diagnosis of PV or ET, who underwent allo-
geneic HSCT between 1994 and 2010 due to progression to MF or
AML and who were reported to the European Group for Blood
and Marrow Transplantation (EBMT) registry by 89 European cen-
ters from 20 different countries. The EBMT database uses PV and
ET sub-classifications at diagnosis. Transformation before trans-
plantation to MF or AML is foreseen by the registry, and centers
are asked to register the initial and the transformation diagnosis
before transplantation. The study included data on: any pre-trans-
plant status of disease; transplants performed after a standard
myeloablative or a reduced intensity conditioning regimen; the
use of either peripheral blood or marrow (thus excluding cord
blood cells) as the source of stem cells; related or unrelated donors;
and any GVHD prophylaxis that varied locally and according to
the study period. The median follow-up from the time of allo-
geneic HSCT was 13 months (range, 0.03-123 months).   
Institutional review board approval was obtained from all par-
ticipating institutions. 
Outcomes
The endpoints of the study were defined according to the
Statistical Guidelines for the EBMT.19 The overall survival was
defined as the probability of survival irrespective of disease state
at any point in time from transplantation. Patients alive at their last
follow-up were censored. The cumulative incidence of relapse
was calculated as the time from transplantation to the first evi-
dence of recurrence or progression of disease, with death with no
prior relapse or progression as a competing risk. Similarly, non-
relapse mortality was defined as the probability of dying without
a previous relapse or progression, considering relapse or progres-
sion as a competing risk. GVHD was diagnosed according to pre-
viously established criteria.9,20,21
Statistical methods
Continuous variables are shown as medians with ranges and
categorical variables as numbers with percentages. Kaplan-Meier
curves were used to analyze survival figures (overall survival,
relapse incidence), while relapse and non-relapse mortality were
considered as competing events and were analyzed by means of
cumulative incidence curves. The log-rank test was used to assess
differences among variable categories. 
We considered differences to be statistically significant if P val-
ues were ≤0.05. The analyses were carried out using SPSS soft-
ware, version 19.0 (SPSS, Chicago, IL, USA).
Results
Patients and transplant characteristics
The characteristics of the patients and donors as well as
transplantation and post-transplantation variables for the
entire group of 250 patients are summarized in Table 1.
This study included 250 consecutive patients with an ini-
tial diagnosis of PV (n=120) or ET (n=130), who under-
went allogeneic HSCT due to progression to MF (n=193)
or AML (n=57). The cohort consisted of 137 males and
113 females with a median age at transplantation of 56
years (range, 22-75 years) and in 52% of cases the interval
between diagnosis and transplantation was 10 years or
more. JAK2V617F mutational status was known for 107
patients (43%). Of all 250 transplants, 80 were performed
after standard myeloablative conditioning and 170 after
reduced intensity conditioning. The preferred source of
stem cells was peripheral blood which was used in 229
patients (92%). Donors were HLA related matched
(n=115) or mismatched (n=2), or unrelated matched
(n=124) or mismatched (n=9). Fifty-four (22%) pairs were
both seronegative for cytomegalovirus. GVHD prophylax-
is was based on cyclosporine A in 179 cases either alone
(n=8) or combined with methotrexate (n=84) or mofetil
mycophenolate (n=87). T-cell-depletion was performed in
vivo with antithymocyte globulin in 134 patients (54%)
and with alemtuzumab in 25 (10%) or ex vivo in 7 (3%). In
the AML group, cytogenetic data were available for 17 of
57 patients (30%) and all karyotypes were attributable,
according to the European LeukemiaNet classification22, to
an intermediate II or adverse prognostic category of risk.
At the time of allogeneic HSCT, in the same group of
patients 22 (39%) were considered in complete remission,
13 (23%) had refractory disease, 14 (25%) had
relapsed/progressive disease, 6 (11%) were untreated,
while the hematologic status was unknown for 2 (3%). A
reduced intensity conditioning regimen was used in 34
patients (58%) (Table 1). In the MF group, the Lille score23
at the time of transplantation was available for 75 patients
(49%). According to this prognostic scoring system, 30
(16%) patients belonged to a low risk group, 37 (19%) to
an intermediate risk one, 8 (4%) to a high risk one; for 118
(61%) patients this information was not known. Among
the whole group of patients with MF at the time of trans-
plantation, 59 (31%) were untreated, 95 (49%) had pro-
gressive disease and 15 (8%) had a minor response; hema-
tologic status was unknown for 24 (12%) (Table 1). 
Main clinical outcomes 
With a median follow-up of 13 months (range, 0.03-123
months), 3-year overall survival and relapse incidences
were 55% and 32%, respectively (Figure 1A,B). In the uni-
variate analysis, overall survival was significantly longer in
younger patients (<55 years, 65% versus 47%, P=0.015)
and in patients with a diagnosis of MF compared to AML
(62% versus 28%, P<0.001) (Figure 1C and Table 2). The
overall survival rate was lower in patients receiving
hematopoietic stem cells from an HLA unrelated donor
than in those receiving a graft from HLA-matched related
donors (50% versus 65%, P=0.085), although the differ-
ence was not statistically significant (Table 2). Older age
and a diagnosis of AML were also risk factors associated
with a higher relapse incidence rate (Table 2). Relapse inci-
dence rate was lower in patients receiving myeloablative
conditioning than in those receiving reduced intensity
conditioning (16% versus 40%, P=0.09), although again
this difference was not statistically significant (Table 2).
Other potential risk factors, such as the initial diagnosis
(PV versus ET), the time from initial diagnosis to transplan-
tation (<10 years versus >10 years), the presence of
JAK2V617F mutation, the disease status at transplantation,
the stem cell source, T-cell depletion and the
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patient/donor cytomegalovirus status, had no impact on
clinical outcomes (Table 2).
Mortality and causes of death
Of the 250 patients studied, 82 (33%) have died. The
most frequent causes of death were relapse or progression
(n=29), infections (n= 24) and GVHD (n=20), resulting in a
non-relapse mortality rate of 28% (Table 3). The 3-year
cumulative incidence of non-relapse mortality was signif-
icantly higher in older patients (>55 years, 35% versus
20%, P=0.032), in those transplanted from an unrelated
donor rather than a related donor (34% versus 18%,
P=0.034) and in patients with a diagnosis of AML com-
pared to MF (29% versus 27%, P=0.045) (Table 2). The
higher non-relapse mortality rate observed in patients
with AML compared to those with MF was mainly due to
a higher frequency of events occurring early after trans-
plantation (e.g. at 6 months) in the patients with AML. 
Graft-versus-host disease
Grade 0-1 acute GVHD occurred in 68% of patients and
grade 2-4 in 27%. In the evaluable patients the rate of
chronic GVHD was 60%, with the extensive form occur-
ring in 37% of patients and the limited form in 23% of
patients. Data about acute and chronic GVHD were
unknown for 10 (4%) and 67 (27%) patients, respectively.
Discussion
In keeping with previous reports our results support the
potential curative effect of allogeneic HSCT in patients
with PV or ET who have progressed to MF or AML.7,8,10-13,24
The main parameters that negatively affected post-trans-
plant outcomes were older age (>55 years), a diagnosis at
transplant of AML and donor type (unrelated versus relat-
ed). Patients younger than 55 years had significantly better
overall and event-free survival compared to those older
than 55 years, because of the significantly higher non-
relapse mortality observed in elderly patients. The
reduced overall survival observed in patients with second-
ary AML was due to a higher incidence of relapse in AML
(53%) compared to MF (28%) patients. Patients trans-
planted earlier in the course of the disease are those who
benefit most from the procedure,8,10,25,26 suggesting  that an
appropriate timing for allogeneic HSCT is crucial to obtain
better results. In this large series of patients we did not
find that a longer interval between initial diagnosis and
transplantation had a negative impact on survival, suggest-
T-cell depletion                                                      248
No                                                                                                           86                    34
In vivo                                                                                                  155                   63
Anti-thymocyte globulin                                                                 134                   84
Alemtuzumab                                                                                    25                   16
Ex vivo                                                                                                   7                     3
GVHD prophylaxis                                                 250
Cyclosporine                                                                                        8                     3
Cyclosporine+methotrexate                                                           84                    34
Cyclosporine+mofetil mycophenolate                                          87                    35
Missing                                                                                                  71                    28
Table 1. Characteristics of the 250 patients, donors and transplantation modalities.
                                                              N. of cases
                                                               evaluable                N.                 %
Patients’ characteristics
Age, years; median 56 (22-75)                            250                                                   
Male/female                                                            250                     137/113            55/45
Initial diagnosis                                                      250
Polycythemia vera                                                                             120                   48
Essential thrombocythemia                                                           130                   52
Interval diagnosis–transplant, years;               250
Median 11 (0.2-38)
≤ 10 years                                                                                            119                   48
10 years                                                                                              131                   52
Diagnosis at time of transplant                          250
Myelofibrosis                                                                                      193                   77
Acute myeloid leukemia                                                                    57                    23
JAK2V617F mutation                                             107
Absent                                                                                                   11                    10
Present                                                                                                  96                    90
Year of transplant                                                  250
Before 2005                                                                                          54                    22
2005-2007                                                                                              68                    27
Onwards 2008                                                                                     128                   51
AML group characteristics
Cytogenetic risk group according to ELN      57
Unknown                                                                                            40                    70
Intermediate 2                                                                                   9                     16
Adverse                                                                                                8                     14
Disease status at transplant                              57
Unknown                                                                                              2                      3
Untreated                                                                                            6                     11
Primary refractory                                                                            13                    23
Relapse/progression                                                                       14                    25
Complete remission                                                                        22                    39
Myelofibrosis group characteristics
Lille score at transplant                                    193
Unknown                                                                                            118                   61
Low risk                                                                                              30                    16
Intermediate risk                                                                             37                    19
High risk                                                                                              8                      4
Disease status at transplant                             193                           
Unknown                                                                                             24                    12
Untreated                                                                                           59                    31
Progression                                                                                       95                    49
Minor response                                                                                15                     8
Donors’ characteristics                                                                                                 
HLA                                                                           250
HLA related matched                                                                        115                   46
HLA related mismatched                                                                   2                      1
Unrelated matched                                                                           124                   50
Unrelated mismatched                                                                      9                      3
CMV status: patient/donor                                  226
-/-                                                                                                            54                    24
-/+                                                                                                          27                    12
+/-                                                                                                           51                    22
+/+                                                                                                         94                    42
Transplant characteristics                                                                                            
Conditioning regimen                                          250
Myeloablative                                                                                       80                    32
Acute myeloid leukemia                                   57                          23                    40
Myelofibrosis                                                     193                         57                    30
Reduced intensity                                                                              170                   68
Stem cell source                                                   250
Peripheral blood                                                                                229                   92
Bone marrow                                                                                       21                     8
Continued in the next column
Continued from the previous column
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ing that the main parameter in terms of better outcome is
probably the type of transformation before transplanta-
tion.
Among transplant-related factors, transplantation from
matched unrelated donors showed an adverse impact on
non-relapse mortality. These results are in keeping with
those recently reported by Rondelli et al., who showed
that after allogeneic HSCT with reduced intensity condi-
tioning with fludarabine/melphalan, the unrelated donor
transplants were associated with a higher risk incidence of
graft rejection and  failure and lower survival.27 It is worth
noting that stem cells were obtained from a mismatched
donor for only 11 patients and this should be carefully
Figure 1. (A) Cumulative overall survival of allogeneic transplanted
patients with transformed ET/PV. (B) Cumulative incidence of relapse
of allogeneic transplanted patients with transformed ET/PV. (c)
Cumulative overall survival of allogeneic transplanted patients with
transformed ET/PV according to diagnosis at transplant.
Table 2. Univariate analysis for the main clinical outcomes evaluated at 36
months after transplant.
Risk factor N. OS P RI P NRM P
(%) (%) (%)
at 3-year at 3-year at 3-year
Overall 250 55 32 28
Age, years
<55 114 65 - 27 - 20 -
≥55 136 47 0.015 39 0.047 35 0.032
Diagnosis at TRX
AML 57 28 - 53 - 29 -
MF 193 62 <0.001 28 0.001 27 0.045
Donor type
Related  115 65 - 35 - 18 -
Unrelated 124 50 0.085 30 0.562 34 0.034
Mismatched 11 30 0.390 35 0.775 49 0.342
Initial diagnosis
PV 120 60 - 34 - 28 -
ET 130 51 0.272 31 0.437 28 0.876
JAK2V617F mutation
Absent 11 36 - 36 - 36 -
Present 96 58 0.072 39 0.483 19 0.094
Unknown 193 55 0.168 27 0.174 33 0.365
Interval diagnosis-TRX
≤ 10 years 119 51 - 34 - 27 -
>10 years 131 59 0.327 31 0.454 29 0.870
Year of TRX
Before 2005 54 61 - 21 - 28 -
2005-2007 68 51 0.382 39 0.094 29 0.899
Onwards 2008 128 64 0.693 28 0.120 23 0.863
Disease status at TRX
Complete remission 23 63 0.652 93 0.200 7 0.178
Relapse/ 90 59 0.991 35 0.479 22 0.704
progression
Untreated      65 61 - 31 - 25 -
Other 59 47 0.181 36 0.768 36 0.454
Conditioning regimen
Myeloablative   80 56 - 16 - 30 -
Reduced intensity 170 55 0.231 40 0.097 27 0.396
CMV status
-/- 54 70 - 22 - 13 -
-/+ 27 55 0.335 41 0.219 13 0.862
+/- 51 55 0.137 19 0.659 35 0.081
+/+ 94 62 0.564 27 0.503 26 0.223
T-cell depletion
No   86 57 - 24 - 28 -
Yes 162 56 0.614 38 0.123 27 0.824
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considered when evaluating the clinical outcome of this
cohort of patients. Since a large proportion of patients
(63%) received a graft subjected to in vivo T-cell depletion,
we observed a relatively low incidence of acute GVHD
grades 2-4, as compared to the incidence that would usu-
ally be expected in patients of such an advanced age.
While intensive GVHD prophylaxis with in vivo T-cell
depletion probably had a positive impact on the incidence
and severity of acute GVHD, this strategy was associated
with a high incidence of severe and fatal infections. 
We observed only a tendency, which did not reach sta-
tistical significance, to a different relapse incidence rate
when a standard myeloablative or reduced intensity con-
ditioning regimen was used. On this topic, conflicting
results have been reported and this uncertainty may be
partly due to the retrospective design of most studies
which have been highly heterogeneous regarding selec-
tion of patients, drugs used in the conditioning, donor
type and stem cell source.8,11,12,25,28 Therefore, although
many results would suggest the use of a busulfan-based
conditioning regimen10,25,29 as most appropriate, this issue
remains a matter of debate and of intense clinical investi-
gation. Other factors, including initial diagnosis (PV versus
ET), presence or absence of the JAK2V617F mutation,
patient/donor cytomegalovirus status, disease status at
transplantation, stem cell source and T-cell depletion, had
no influence on clinical outcome in our cohort of patients.
We found a significantly higher (90%) than expected pro-
portion of patients with mutated JAK2V617F (70%) con-
sidering the cohort composition: this discrepancy is likely
due to a reporting bias in the registry in favor of patients
carrying the mutation. Unfortunately, the data required
for calculating the Lille score were not available in the
database for a large proportion of patients and similarly
the data to calculate the more recent prognostic scoring
systems, created to identify higher risk patients with pri-
mary MF,23,30-32 were also missing. Although this lack of
information clearly represents a weakness of our study, it
should be considered that none of these prognostic scoring
systems has been validated for MF secondary to a previ-
ous PV and ET. 
As for all multicenter retrospective studies some limita-
tions need to be considered also for our study. First, this
retrospective analysis collected data from many different
European centers performing transplants over a long peri-
od of time with marked heterogeneity in terms of the
patients’ age, co-morbidities, pre-transplant transfusion
dependency, use of conditioning regimens and GVHD
prophylaxis. Moreover, although to our knowledge it is
the largest analysis published, it still does not allow an in-
depth evaluation of the different risk factors that may
characterize these patients, such as previous cytoreductive
treatments or cytogenetics at transplantation. Similarly, it
was not possible to get an accurate estimate of progres-
sion-free survival. The lack of this information in the data-
base probably reflects the difficulties in assessing response
in these diseases. Finally, the follow-up of the patients
reported in the registry was relatively short, although we
consider that this follow-up was probably sufficient to
enable a correct evaluation of the main clinical outcomes.
However, even if definitive conclusions cannot be drawn
due to these limitations, the clinical implications of our
findings are potentially very important: indeed, the poten-
tial curative effect of allogeneic HSCT is more consistently
supported, with a similar 3-year survival rate compared to
that of high-risk patients with MF who did not undergo
allogeneic HSCT,33 with the advantage that transplanted
patients may be definitely cured. These EBMT data are
consistent with those recently reported by other coopera-
tive study groups,8,28 indicating that overall survival follow-
ing allogeneic HSCT may reach approximately 50%. 
Nonetheless, non-relapse mortality and relapse remain
unsolved problems for which future studies should
explore the potential benefits of the use of new molecular
therapies, such as Jak2 inhibitors, before and/or after allo-
geneic HSCT. In fact, these drugs have been shown to
reduce spleen size and constitutional symptoms signifi-
cantly, despite being unable to cure MF.34 The effect on
spleen size could reduce the number of patients undergo-
ing splenectomy, which cannot be recommended as a
standard procedure before transplantation. Indeed, despite
a favorable impact on engraftment,8,35 splenectomy is asso-
ciated with significant surgery-related mortality (often
exceeding 10%) and it may also be associated with an
increased risk of relapse.25
In conclusion, this large retrospective study confirms
that allogeneic HSCT is potentially curative for end-stage
PV/ET patients progressing to MF or AML. Innovative
treatment approaches with new molecular targeted thera-
pies may increase the number of patients eligible for trans-
plantation and reduce the risk of relapse and non-relapse
mortality, but they need to be assessed in prospective clin-
ical trials.
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Table 3. Causes of death (n=82).
Causes of death                                   N.                             (%)
Relapse/progression                                   29                                    35
Infection                                                         24                                    29
GVHD                                                               20                                    25
Organ damage/failure                                   1                                    <1
Cerebral hemorrhage                                   1                                     <1
Other causes                                                 10                                     4
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